Replies to post #329236 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

Awesome. Thanks, Survivor2012.

[VikingInvest]

Thanks for the update.

[exkitteryff]

Thanks for the update Survivor

[anders2211]

thank you Survivor2012

[BioInvestor4]

Thank you for the update!

[anders2211]

Dave did most of talking and displayed frustration with the 100s of (the same) questions and inquiries he receives "from 6am to 2am" daily. He said every time stock drops 5 cents the phones light up

that is the consequence when solely working with retail investors...
Listed companies with large companies see large investors only once per year at the ASM..

[flipper44]

Thanks. The report would indicate DI is being illogical. Timeline unpredictable but instead of more PRs, he wants to provide less, and he thinks this will reduce calls in. He says data lock PR accurate, but this leaves TLD up in the air. From this, he wants people to chill out. Hmm.

[Harry1969]

Dave did most of talking and displayed frustration with the 100s of (the same) questions and inquiries he receives "from 6am to 2am" daily

Is that not what an IR job entails? Maybe if he used some of the other tools at his disposal he could reduce his frustration - frequent PRs, 8Ks, etc.

Thanks for the summary though, much appreciated! Was there any talk of the “quiet period”?

[eagle8]

Thank you Survivir2012 for sharing.

GLTU

[Hopeforthefuture3]

Survivor, thanks for sharing.
If Innes is frustrated with all the questions (mostly the same) then why doesn't the company simply put out a letter to shareholders or a pr addressing the questions so all can know the current status (to the degree they are willing to share)?
Seems a very simple solution. Or perhaps try their first ever quarterly conference call.

This 'quiet period' is that something nwbo announced or only from calls to the company?

Good luck all

[br8k0ut]

Thank you for the update

[Poor Man -]

Nice summary. Who (and how) would anybody else be interested in a combo trial involving Keytruda? The Duffy response sounds like a dodge.

“He did confirm that Duffy attended LL's presentation (how would he know that?) and when Duffy left NWBO, he went back to Merck to a nice (Director position) promotion. He confirmed there is a lot of interest (not just from Merck) in "succesful" and ongoing Keytruda combo trial being paid for and conducted by LL/UCLA.”

[learningcurve2020]

That’s a lot about Dave’s feelings but kind of light on facts. What’d he say about the endpoint changes?